From September 16 to 19, the 20th China-Asean Expo was held as scheduled in Nanning, Guangxi. As the high-level forum of the expo, the second China-Asean Forum on the Peaceful Use of Nuclear Technology was opened in the same period. With the theme of "Nuclear Power for a Better Future", the Forum will further promote the peaceful use of nuclear energy and nuclear technology, and jointly build five major homes of peace, tranquility, prosperity, beauty and friendship between China and ASEAN. At the main forum, the China Isotope and Radiation Industry Association announced the demonstration project of China-Asean cooperation in the peaceful use of nuclear technology, and HTA Co., Ltd.'s "Supply of radioactive pharmaceutical products in Indonesia" project stood out in the list, which is the award of Atomtech after the first forum.

　　Asean countries are one of the focuses of HTA's overseas market development and an important direction of its international strategic layout. In recent years, HTA Co., Ltd. has devoted itself to the ASEAN key markets, conducted in-depth research on the local market situation and regulatory policies, actively sought high-quality trade partners, and finally achieved the export of radioactive drugs to Indonesia, which is the first export of domestic radioactive drugs to ASEAN countries, becoming a successful practice and typical demonstration of the export of domestic short half-life radioactive drugs.

　　It is reported that the "supply of finished radioactive drugs in Indonesia" project was launched in 2018, and the local access license was obtained in Indonesia in 2020. Through the joint efforts of the two sides, in December 2021, the iodine [131I] sodium oral solution produced by HTA was shipped as scheduled, cleared customs, and safely delivered to the local hospital. In January 2022, the domestic sodium iodide [131I] oral solution successfully completed the diagnosis and treatment of 4 cases in the local hospital, and the product quality and service were highly recognized by users. Based on the above experience, on September 4, 2023, HTA Co., Ltd. and Indonesian enterprises officially signed a project business contract at the 2023 China International Trade in Services Fair, intended to provide stable supply of sodium iodine [131I] oral solution for Indonesia, which will effectively improve the long-term shortage and instability of drug supply in Indonesia. Strengthen the localization ability of the local pharmaceutical industry, and improve the efficiency and quality of nuclear medicine diagnosis and treatment.

　　HTA will take this award as a spur to promote its international business process. Make use of the China-Asean Framework Agreement on Comprehensive Economic Cooperation and the Regional Comprehensive Economic Partnership (RCEP) and other policies to improve the economy of the project, build the "Belt and Road" with high quality based on ASEAN, help realize the goal of HTA being "the leader of international nuclear drug development", and actively practice the economic and trade cooperation under the China-Asean comprehensive strategic partnership. It will make new and greater contributions to continuously deepening the cooperation between China and ASEAN countries in the field of nuclear technology application.